D8Y (D8Y) News
Follow D8Y (D8Y) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Sandoz Q3 Sales Miss Expectations on Europe Supply Constraints
Vontobel's Stefan Schneider says supply constraints for biosimilar drugs and a challenging German market hurt Sandoz Group's third-quarter sales.
EARNINGS | Oct 28, 2026, 07:45 AM UTC
M
Sandoz Lowers Sales Growth Guidance, Raises Core Earnings Margin Forecast
Sandoz lowered its full-year sales growth guidance and raised its core earnings margin forecasts after short-term biosimilar supply constraints weighed on third-quarter results. It now expects net sales growth of 5–6% at
EARNINGS | Oct 28, 2026, 06:50 AM UTC
M
Sandoz 9M net sales rise 5% at constant currency
EQUITY | Oct 28, 2026, 06:09 AM UTC
L
Sandoz Group AG (D8Y) Opens High-Volume Biosimilar Facility in Slovenia
Sandoz opened a high-tech, high-volume biosimilar drug substance manufacturing center in Lendava, Slovenia, expanding in-house capacity and flexibility across its European network.Material DetailsContext by AI AnalystThi
NEWS | Sep 29, 2026, 05:02 AM UTC
L
Sandoz opens advanced high-volume drug substance manufacturing centre in Lendava, significantly strengthening in-house capacity and flexibility across leading European biosimilar network
Sandoz Group AG/ Key word(s): ExpansionSandoz opens advanced high-volume drug substance manufacturing centre in Lendava, significantly strengthening in-house capacity and flexibility across leading European biosimilar ne
NEWS | Sep 29, 2026, 05:02 AM UTC
H
Sandoz Sales Might Fall Short of Expectations, But Guidance Looks Safe — Market Talk
Sandoz Group's third-quarter sales might come in slightly below consensus expectations, but the Swiss maker of generic drugs is likely to reiterate its full-year guidance nevertheless, analysts at J.P. Morgan say in a re
EARNINGS | Sep 25, 2026, 11:52 AM UTC
M
Nestle reviews options for Russia unit after external administrators
Nestle said it is assessing options for its Russian unit after Moscow transferred control to external administrators; its shares fell nearly 2% on the news.
EQUITY | Sep 18, 2026, 09:28 AM UTC
M
Sandoz approval for generic Ozempic in Canada draws mixed outlook
TradingView News market talk says Sandoz’s Canada approval for a generic version of Novo Nordisk’s Ozempic is positive, but RBC Capital Markets says the size of the upside is difficult to gauge.
EQUITY | Sep 18, 2026, 09:18 AM UTC
M
Sandoz partners with mAbxience on emicizumab biosimilar
Sandoz (SDZ.SW, SDZNY) announced a collaboration with mAbxience for a proposed emicizumab biosimilar; financial terms were not disclosed.
EQUITY | Sep 18, 2026, 06:13 AM UTC
M
Sandoz receives Canada approval for generic Ozempic
Sandoz Group said Canada’s drug regulator has approved its generic version of Novo Nordisk’s Ozempic, supporting its GLP-1 portfolio plans.
REGULATION | Sep 18, 2026, 05:34 AM UTC
L
Sandoz biosimilar expansion to initially rely on external assets
Sandoz plans to expand its biosimilar-drug portfolio over the next decade and a half, with the initial push relying on external assets, according to J.P. Morgan analysts.
EQUITY | Sep 09, 2026, 12:54 PM UTC
M
Sandoz unveils Bio 100 strategy to launch 100+ biosimilars by 2040
Company says Bio 100 strategy targets launching over 100 biosimilars by 2040. It aims to double net sales by 2035 and reach a core EBITDA margin above 30%, backed by vertical integration and regulatory streamlining.
EQUITY | Sep 08, 2026, 09:42 PM UTC
L
Sandoz Bio 100 targets 100+ biosimilars by 2040
Sandoz’s Bio 100 plan targets over 100 biosimilars by 2040, alongside doubling net sales by 2035 and shifting to a biosimilar-led, vertically integrated model.
EQUITY | Sep 08, 2026, 05:59 PM UTC
L
Sandoz Bio 100 targets 30%+ EBITDA margin by 2040
Sandoz’s Bio 100 plans expand its biosimilar portfolio to over 100 assets by 2040, targeting more than doubling net sales by 2035 and a core EBITDA margin above 30%.
EQUITY | Sep 08, 2026, 11:59 AM UTC
M
Sandoz plans $300 million biosimilar facility in Ljubljana
Sandoz Group plans to invest around $300 million to build a new biosimilar manufacturing facility in Ljubljana, Slovenia. The facility is expected to start operations in 2029 and add 8,000 litres of production capacity.
EQUITY | Sep 08, 2026, 08:13 AM UTC
L
Sandoz’s Bio100 targets 100+ biosimilars by 2040
Bio100 plans to grow the biosimilar portfolio to over 100 by 2040 and target 80% LoE coverage. It targets mid- to high single-digit sales growth through 2030, doubling net sales by 2035 and core EBITDA margin above 30%.
EQUITY | Sep 08, 2026, 07:17 AM UTC
M
European shares slip as oil lifts inflation worries; Novartis drags
European stocks edged lower as rising oil prices revived inflation worries and supply concerns tied to a prolonged Middle East conflict. The STOXX 600 fell 0.2% to 648.41. Novartis was under pressure after a second drug
COMMODITIES | Sep 08, 2026, 07:11 AM UTC
M
Sandoz investor roadmap seen well-received as 2030 guidance set
Vontobel’s Stefan Schneider said Sandoz’s years-ahead roadmap is likely to be well received after it confirmed a 2028 outlook, set new 2030 guidance ahead of Vontobel estimates, and projected an acceleration.
EQUITY | Sep 08, 2026, 07:00 AM UTC
L
Sandoz sets 2025-2030 growth and core EBITDA margin targets
Sandoz reaffirmed its prevailing mid-term outlook to 2028 and introduced a 2025-to-2030 outlook. It targets mid-to-high single-digit average annual net sales growth at constant currencies and a core EBITDA margin level.
EARNINGS | Sep 08, 2026, 06:10 AM UTC
L
Sandoz targets more than double net sales by 2035
Sandoz says it aims to more than double net sales from 2025 to 2035 and to achieve a core EBITDA margin above 30% by 2035, while keeping its commitment to the midterm outlook to 2028.
EARNINGS | Sep 08, 2026, 05:46 AM UTC
L
Sandoz targets mid-to-high single-digit sales growth through 2030
Sandoz Group set a sales growth outlook for 2030, targeting mid-to-high single-digit growth.
EARNINGS | Sep 08, 2026, 05:20 AM UTC
L
Sandoz to invest in Ljubljana drug-substance facility to expand biosimilar capacity
Sandoz Group AG plans to invest in a new drug-substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity.
EQUITY | Sep 08, 2026, 05:10 AM UTC
L
Sandoz to invest $300M in disposable fed-batch tech
Sandoz plans a $300M investment in disposable fed-batch technology to expand in-house capacity.
CENTRAL_BANK | Sep 08, 2026, 05:08 AM UTC